Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAM-002A in Relapsed/Refractory B-Cell NHL
NCT02594384Phase 1Completed
- Sponsor
- OrphAI Therapeutics
- Start
- Oct 2015
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of apilimod in B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL) (4 arms), sponsored by OrphAI Therapeutics. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Oct 2015; status: completed.
02
Drugs
apilimod
03
Conditions
B-cell non-Hodgkin lymphomachronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02594384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02594384.